Expert Review of Neurotherapeutics
Q1 Journal
Journal
Country
United Kingdom
Western Europe
Subject Area and Category
Medicine
└
Neurology (clinical)
Q1
└
Pharmacology (medical)
Q1
└
Neuroscience (miscellaneous)
Q2
Publisher
SJR 2025
1.106
Q1
SJR Score
H-Index
110
Citations / Doc (2yr)
4.13
Total Docs. (latest)
113
Total Citations (3yr)
1,192
Publication type
Journals
ISSN
14737175, 17448360
Coverage
2001-2026
Journal Rank
#4,138
Subject Categories
Neurology (clinical)
Q1
Pharmacology (medical)
Q1
Neuroscience (miscellaneous)
Q2
Subject Areas
Aims & Scope
Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry.
Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points
Abstracting & Indexing
Scopus
Google Scholar
Web of Science
Medline
Embase
Detailed Metrics
| Total Docs. (latest) | 113 |
| Total Docs. (3 years) | 299 |
| Total Refs. | 11,574 |
| Total Citations (3 years) | 1,192 |
| Citable Docs. (3 years) | 260 |
| Citations / Doc. (2 years) | 4.13 |
| Ref. / Doc. | 102.42 |
| % Female | 37.7% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.